Fertility
Fertility: Why no one talks about ICI
ICI is being brought back by Béa Fertility in an attempt to level the playing field

Equal and equitable access to fertility care remains a challenge for the over 48 million couples struggling to conceive. We meet Tess Cosad, co-founder and CEO of Béa Fertility, and deep dive into the world of ICI.
IVF treatment is booming all over the world and according to the European Society of Human Reproduction and Embryology (ESHRE), IVF has even started to play a role in demographic analyses.
Since the world’s first successful cycle, the global IVF market has grown and is currently valued at around US$15bn.
But while IVF and IUI remain the most popular forms of assisted conception, they are not the only ones out there.
Intracervical insemination, known as ICI, is a form of home insemination treatment that, unlike IVF where the egg is fertilised with sperm in a laboratory, uses a silicone cap to hold the sperm against the cervix for an extended amount of time.
“ICI used to be the de facto fertility treatment, but when IVF and IUI came along, it fell out of favour,” says Tess Cosad, co-founder of Béa Fertility.
ICI is now being brought back by Béa in an attempt to level the playing field when it comes to assisted conception and provide access to affordable fertility treatment.
“The human, exciting journey of creating a family often becomes the source of stress, shame, struggle and desperation,” says Cosad. “Our idea is to empower people with something that they can do in the comfort, safety, privacy, intimacy of their home because that family-building journey should start in your home not in the clinic.
“For us, the very nature of the product is such that we hope it is a less stressful experience. In addition to the kit we provide, we’re also building a digital product to support people’s mental health and give them access to coaches who can be there for them and answer their questions.”

According to the World Health Organisation (WHO), between 48 million couples and 186 million individuals struggle with infertility globally.
But while vital for some patients, IVF and similar treatments currently account for less than three per cent of infertility services, deepening global inequalities in fertility care.
“The delta between who is getting IVF and who really is struggling to create a family is so significant because most people can’t afford it,” explains Cosad.
“In the US there are 510 fertility clinics as of this year. That’s about 10 per state which means that some would have to travel for more than 24 hours to get to a fertility clinic.
“Because going through fertility treatment can be deeply stressful, our goal is to take out some of the stress by allowing people to use the kit in the privacy of their home as well as taking out the financial stress.”
Currently, IUI, although less expensive than IVF, is estimated to be between four to six times the cost of ICI.
Analysis suggests that procedures including egg freezing, IVF and surrogacy have become a top workplace perk as companies try to attract talent and remain competitive in a tight labor market.
However, Cosad is hopeful that, by expanding access to fertility care to everybody who needs support, Béa will make a difference in this space.
“The clinics know that they’re not helping enough people,” says the founder. “They’re looking for ways to reach out and support more families and we’re one of those ways.
“We won NIHR funding from the National Institute for Health Research and that is the beginning of us starting to do the trials needed to get into the NHS. But we are also looking at partnering with clinics to be able to support our users if the treatment doesn’t work for them.
“There are so many other countries in the world where there’s a lot of cultural shame and stigma around fertility care and I believe we can really support them.
“We’re launching in the UK next year,” Cosad continues. “Nine months after that, hopefully the first baby will come along and in five years, I hope we will be able to proudly look back at the number of people we’ve helped.”
Fertility
Gum disease may impair female fertility and egg quality – study
Fertility
AI could transform ovarian care through personalisation, study finds

AI could transform ovarian care by personalising cancer and fertility treatment, but more clinical validation is needed before routine use.
A systematic review and meta-analysis found AI models showed high diagnostic accuracy for ovarian cancer when combining data such as ultrasound scans and blood test results.
Across 81 studies, AI models correctly identified ovarian cancer in around nine out of 10 cases, with pooled rates of 89 to 94 per cent.
They were also highly accurate at ruling out ovarian cancer when it was not present, with specificity of 85 to 91 per cent.
The analysis also found that explainable AI tools could predict complete surgical cytoreduction in advanced ovarian cancer.
Complete surgical cytoreduction means removing all visible cancer during surgery, which can be an important goal in treatment planning.
The tools achieved a pooled AUC of 0.87. AUC is a measure of how well a model distinguishes between different outcomes, with higher scores showing stronger performance.
In reproductive medicine, AI algorithms helped physicians optimise ovarian stimulation protocols and predict follicular growth during IVF.
Ovarian stimulation is the use of hormones to encourage the ovaries to produce eggs, while follicles are the small sacs in the ovaries where eggs develop.
The review found AI could reliably model ovarian response in IVF with a pooled AUC of 0.81.
However, researchers said challenges remain in translating promising research findings into routine clinical practice.
They identified substantial variation across studies, driven by retrospective study designs, variable AI systems and a lack of standardised validation.
Only 22 per cent of analysed studies reported prospective, multicentre external validation, where models are tested forward in time across multiple healthcare settings.
The authors called for rigorous validation to help close the gap between research and routine clinical practice, alongside standardised methodological and reporting frameworks, smooth integration with clinical workflow and robust governance to support responsible and ethical AI use.
They concluded: “Artificial intelligence is a transformative force in the management of ovarian conditions.
“In gynaecologic oncology, AI enhances every phase of care, from early detection and accurate diagnosis to prognostic stratification and surgical planning.”
In reproductive medicine, AI personalises ovarian stimulation and refines the diagnosis of heterogenous endocrine disorders such as PCOS.
PCOS, or polycystic ovary syndrome, is a hormonal condition that can affect periods, skin, weight and fertility.
Fertility
Housing, work and fertility stop Britons having the families they want – research
Opinion4 weeks agoWhat Maternal Mental Health Month reveals about where postpartum support actually breaks down
Menopause6 days agoPerimenopause misinformation ‘putting women at risk’
Insight4 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Adolescent health3 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Hormonal health3 weeks agoPCOS renamed after decade-long campaign to end ‘cyst’ misconception
Events4 weeks agoWHIS 2026 unveils agenda and first speakers for the leading women’s health summit
Menopause3 weeks agoCBT shows promise for menopause insomnia and hot flashes
Insight4 weeks agoOnline abuse and deepfakes ‘pushing women out of public life’














61 Comments